» Articles » PMID: 38578318

Cancer History and Physical Function in Patients with Cardiovascular Disease

Abstract

Both cancer and cardiovascular disease (CVD) cause skeletal muscle mass loss, thereby increasing the likelihood of a poor prognosis. We investigated the association between cancer history and physical function and their combined association with prognosis in patients with CVD. We retrospectively reviewed 3,796 patients with CVD (median age: 70 years; interquartile range [IQR]: 61-77 years) who had undergone physical function tests (gait speed and 6-minute walk distance [6MWD]) at discharge. We performed multiple linear regression analyses to assess potential associations between cancer history and physical function. Moreover, Kaplan-Meier curves and Cox regression analyses were used to evaluate prognostic associations in four groups of patients categorized by the absence or presence of cancer history and of high or low physical function. Multiple regression analyses showed that cancer history was significantly and independently associated with a lower gait speed and 6MWD performance. A total of 610 deaths occurred during the follow-up period (median: 3.1 years; IQR: 1.4-5.4 years). The coexistence of low physical function and cancer history in patients with CVD was associated with a significantly higher mortality risk, even after adjusting for covariates (cancer history/low gait speed, hazard ratio [HR]: 1.93, P < 0.001; and cancer history/low 6MWD, HR: 1.61, P = 0.002). Cancer history is associated with low physical function in patients with CVD, and the combination of both factors is associated with a poor prognosis.

References
1.
Barac A, Murtagh G, Carver J, Chen M, Freeman A, Herrmann J . Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next Level. J Am Coll Cardiol. 2015; 65(25):2739-46. PMC: 4484773. DOI: 10.1016/j.jacc.2015.04.059. View

2.
Hayek S, Ganatra S, Lenneman C, Scherrer-Crosbie M, Leja M, Lenihan D . Preparing the Cardiovascular Workforce to Care for Oncology Patients: JACC Review Topic of the Week. J Am Coll Cardiol. 2019; 73(17):2226-2235. PMC: 7153911. DOI: 10.1016/j.jacc.2019.02.041. View

3.
Armstrong G, Oeffinger K, Chen Y, Kawashima T, Yasui Y, Leisenring W . Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol. 2013; 31(29):3673-80. PMC: 3804290. DOI: 10.1200/JCO.2013.49.3205. View

4.
Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D . Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin. 2016; 66(4):309-25. DOI: 10.3322/caac.21341. View

5.
Florido R, Daya N, Ndumele C, Koton S, Russell S, Prizment A . Cardiovascular Disease Risk Among Cancer Survivors: The Atherosclerosis Risk In Communities (ARIC) Study. J Am Coll Cardiol. 2022; 80(1):22-32. PMC: 9638987. DOI: 10.1016/j.jacc.2022.04.042. View